Xu, Yaoxian
Kuppe, Christoph http://orcid.org/0000-0003-4597-9833
Perales-Patón, Javier http://orcid.org/0000-0003-0780-6683
Hayat, Sikander http://orcid.org/0000-0001-5919-8371
Kranz, Jennifer
Abdallah, Ali T.
Nagai, James
Li, Zhijian
Peisker, Fabian http://orcid.org/0000-0003-0123-8179
Saritas, Turgay http://orcid.org/0000-0002-6691-9218
Halder, Maurice http://orcid.org/0000-0003-2386-9684
Menzel, Sylvia
Hoeft, Konrad http://orcid.org/0000-0002-0265-0061
Kenter, Annegien http://orcid.org/0000-0002-1040-2308
Kim, Hyojin
van Roeyen, Claudia R. C.
Lehrke, Michael
Moellmann, Julia
Speer, Thimoteus http://orcid.org/0000-0002-2491-6393
Buhl, Eva M. http://orcid.org/0000-0003-0627-9228
Hoogenboezem, Remco
Boor, Peter http://orcid.org/0000-0001-9921-4284
Jansen, Jitske
Knopp, Cordula
Kurth, Ingo http://orcid.org/0000-0002-5642-8378
Smeets, Bart
Bindels, Eric http://orcid.org/0000-0001-9502-669X
Reinders, Marlies E. J.
Baan, Carla
Gribnau, Joost http://orcid.org/0000-0001-5645-4691
Hoorn, Ewout J.
Steffens, Joachim
Huber, Tobias B. http://orcid.org/0000-0001-7175-5062
Costa, Ivan http://orcid.org/0000-0003-2890-8697
Floege, Jürgen
Schneider, Rebekka K. http://orcid.org/0000-0002-0749-1565
Saez-Rodriguez, Julio http://orcid.org/0000-0002-8552-8976
Freedman, Benjamin S.
Kramann, Rafael http://orcid.org/0000-0003-4048-6351
Article History
Received: 11 November 2021
Accepted: 9 September 2022
First Online: 27 October 2022
Competing interests
: R.K. reports unrelated funding from Travere Therapeutics, Galapagos and Novo Nordisk and unrelated honoraria from Bayer, Pfizer, Grünenthal and Novo Nordisk. S.H. reports unrelated funding from Novo Nordisk. J.S.R. reports unrelated funding from GSK and Sanofi and unrelated fees from Travere Therapeutics and Astex Therapeutics. All other authors have nothing to disclose.